Legislation
A federal district court on May 19 issued a temporary restraining order prohibiting the Trump administration from enforcing its February pause on NIH research grant funding. The ruling in Democratic Attorneys General Association v. Trump marks the first judicial block on the administration’s science funding freeze, setting up a high-stakes constitutional confrontation over executive authority over federal research infrastructure.
The Pause and the Litigation
On February 21, 2026, the NIH published a notice in the Federal Register halting payments on all active grants and cooperative agreements pending a review of awardee institutions’ alignment with administration priorities. The notice cited Executive Order 14212 on “Ensuring Lawful Governance and Removing Regulations,” a January 2025 directive that instructed agencies to conduct equity and diversity reviews across federal programs. NIH acting director Dr. Monica Bertino issued the notice under a delegation from HHS Secretary Robert Fitts.
The pause affected approximately 38,700 active grants with a combined annual value of roughly $19.4 billion. Researchers at over 2,400 institutions — including major research universities, teaching hospitals, and independent labs — experienced disruptions to ongoing projects. Three Democratic state attorneys general filed for a TRO on March 3, arguing the pause constituted a substantive rulemaking that required notice-and-comment under the Administrative Procedure Act and exceeded the executive order’s scope as applied to multi-year appropriations.
The district court found the plaintiffs demonstrated “likely success on the merits” of their APA claim. The notice, the court held, imposed new conditions on existing grant obligations not contemplated by the underlying appropriation statutes, and the agency’s failure to provide a 30-day comment period rendered the action “arbitrary and capricious.” The court further found that the ongoing funding disruption imposed irreparable harm — research projects face workforce terminations, equipment purchase cancellations, and publication delays that cannot be remedied through damages.
The Constitutional Question
The administration’s central argument is that the President holds inherent Article II authority to direct the execution of federal spending, and that the February notice was an exercise of that authority rather than a “legislative rule” subject to APA procedures. DOJ attorneys have argued that appropriations statutes vests funding authority in the executive branch, not in the institutional recipients, and that the pause constitutes a legitimate exercise of “pause and review” power consistent with prior administrations’ practices.
The district court rejected this framing. Citing Youngstown Sheet & Tube Co. v. Sawyer and the Supreme Court’s 2025 decision in FDA v. Alliance for Hippocratic Medicine on administrative deference, the court said the executive cannot, through an agency directive, impose conditions on funding that Congress did not authorize. The court noted that NIH grants are multi-year obligations backed by appropriations acts — not discretionary executive spending — and that altering them mid-cycle requires congressional authorization or a formal APA rulemaking process.
“The executive cannot, through a delegated agency director operating under a broadly-worded executive order, rewrite the terms on which congressionally appropriated funds are disbursed. If the administration wishes to condition NIH funding on ideological alignment, it must go through Congress — not circumvent the APA and claim Article II as a shield.”
Broader Congressional Context
The timing of the ruling intersects with the ongoing FY2026 appropriations debate on Capitol Hill. The Senate Appropriations Committee advanced its FY2026 Labor-HHS bill on May 14 — a measure that includes $47.3 billion for NIH, a $2.1 billion increase over FY2025. Senate appropriators included report language directing NIH to “maintain the continuity of peer-reviewed research commitments” and warning that “interference with established grant timelines undermines the scientific integrity of the federal research enterprise.”
The House version of the Labor-HHS appropriations measure, passed by the committee on May 16, contains broader policy riders that have drawn veto threats from the White House. The House bill includes a provision codifying the NIH’s 10 percent indirect cost cap — a measure directly at odds with the administration’s 2025 executive order on DEI contracting. The Senate version does not include the cap provision, leaving the two chambers on a collision course in conference.
The NIH litigation has attracted amicus briefs from 64 research universities, the American Association for the Advancement of Science, and a coalition of 23 scientific societies. Their brief argues that the pause has already caused “measurable brain drain” as early-career researchers accept positions abroad, and that a prolonged disruption would set U.S. science back a generation relative to China and the European Union.
What Comes Next
The TRO remains in effect until the district court rules on the preliminary injunction motion, scheduled for argument on June 3. The administration has signaled it will appeal any adverse ruling to the relevant circuit court and has not ruled out requesting emergency Supreme Court intervention.
Congress faces pressure from two directions. Senate appropriators are navigating the chamber’s reconciliation instructions — the Senate GOP’s $72 billion reconciliation allocation for DHS and related agencies leaves limited room for additional non-defense spending increases, making the NIH bump a potential negotiating chip. Meanwhile, House Republican appropriators face pressure from the Freedom Caucus to use the appropriations process to codify the administration’s funding pause more formally.
On the legislative side, Senate Finance Committee staff have circulated a draft “NIH Continuity Assurance Act” that would prohibit HHS from pausing or revoking peer-reviewed grants without a 60-day congressional notification period and a formal finding that the pause is “necessary for national security.” The draft has bipartisan co-sponsorship but faces procedural headwinds under the Senate’s reconciliation time limit.
The NIH litigation now ranks alongside the reconciliation debate and the FY2026 appropriations fight as one of the three most consequential legislative battles of the summer. All three touch the same underlying question: how far can the executive branch go in reshaping federal spending priorities without Congress, and what judicial and legislative check exists when it overreaches?
Robert Callahan is a legal and legislative analyst for Media Hook, specializing in constitutional law, regulatory frameworks, and the intersection of legislation and executive action.